In addition to being a time and cost intensive process, bioavailability enhancement is fraught with several challenges; considering the expertise available with specialty service providers to improve the pharmacokinetic properties of novel molecules, drug developers are actively outsourcing their requirements
Roots Analysis is pleased to announce the publication of its recent study, titled, “Drug Bioavailability Enhancement Market (2nd Edition), 2022-2035”. The study features an in-depth analysis, highlighting the capabilities of bioavailability enhancement technology and service providers engaged in this domain.
Amongst other elements, the report features:
A detailed assessment of the overall market landscape of bioavailability enhancement technology and service providers
Elaborate profiles of various prominent players that are engaged in offering bioavailability enhancement technologies and services.
An analysis of partnerships that have been inked between several stakeholders engaged in providing bioavailability enhancement services and technologies, during the period 2013-2022.
A detailed review of more than 5,800 peer-reviewed, scientific articles related to research on bioavailability enhancement of drug compounds and / or drug candidates.
An in-depth analysis of the patents that have been filed / granted for bioavailability enhancement approaches and technologies since 2003.
An in-depth analysis of completed, ongoing, and planned clinical studies related to bioavailability enhancement of various drug compounds and / or candidates.
An insightful framework evaluating the bioavailability enhancement approaches based on various parameters, such as number of technologies, number of approved drugs, trends highlighted in published literature and patents, and business models adopted by industry stakeholders. It also provides a value addition matrix for respective bioavailability enhancement approaches currently employed by stakeholders.
An elaborate analysis in order to estimate the current and future demand for bioavailability enhancement technologies and services, based on several relevant parameters, such as drug class (new drug approvals and generics), BCS classification (BCS II drugs and BCS IV drugs) and dosage form (liquids, solids, semi-solids, and fine particles / powders) for the period 2022-2035. Kindly note that input parameters considered for this analysis include number of New Chemical Entity (NCE) candidates and generic / reformulated drug products that are likely to undergo formulation development over the period of next 13 years.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):
New Drug Approvals
BCS II Drugs
BCS IV Drugs
Bioavailability Enhancement Approach
Fine Particles / Powders
Middle East and North Africa (MENA)
Rest of the World
Key companies covered in the report
Adare Pharma Solutions
Lubrizol Life Science Health
Pace Life Sciences
WuXi STA (a subsidiary of WuXi AppTec)
Get more details on the Bioavailability Enhancement Technologies and Services Market report https://www.rootsanalysis.com/reports/view_document/bioavailability-enhancement-technologies-and-services/198.html
Learn from experts: do you know about these emerging industry trends?
Can The Next Generation Drug Conjugates Revolutionize The Rare Disorder Domain?
Biopharmaceutical Filtration: A Deep Dive
Top 5 Companies Developing Allogeneic Cell Therapies
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
+1 (415) 800 3415